Business
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled for completion Q3 2025 and Phase 1b dose-range finding scheduled for completion H2 2026 NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the
About this update from Corbus Pharmaceuticals Holdings, Inc.
[{"type":"image","alt":"Corbus Pharmaceuticals Holdings, Inc.","displaySize":"","headline":null,"caption":"Corbus Pharmaceuticals Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/b0d3415d4cf3d45a0ffce87aeff8ec18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/z7Iu.c3o3K9KWXFezgFH1w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b0d3415d4cf3d45a0ffce87aeff8ec18","width":300,"height":169}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"CB1 inverse agonism is a clinically validated mechanism to induce weight loss ","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabant","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"SAD/MAD Phase 1 trial scheduled for completion Q3 2025 and Phase 1b dose-range finding scheduled for completion H2 2026","length":119,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":283,"olType":false},{"type":"text","content":"NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the single ascending dose / multiple ascending dose (SAD/MAD) portion of the Phase 1 trial of CRB-913 for the treatment of obesity. The study is being conducted in the United States under an open IND.","length":446,"tagName":"p"},{"type":"text","content":"CRB-913 is a second-generation, highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist drug designed to treat obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss but the first generation of this class (e.g., rimonabant) was abandoned due to the potential risk of neuropsychiatric adverse events. A second generation of peripherally restricted CB1 inverse agonists is now being explored (e.g., monlunabant and CRB-913). ","length":480,"tagName":"p"},{"type":"text","content":"Pre-clinical data presented at Obesity Week 2024 demonstrated CRB-913 is markedly more peripherally restricted than both monlunabant and rimonabant. In non-clinical models, CRB-913 has a brain-to-p...